Isoderm

Isotretinoin

Method of action: Antiacne, Anti-Inflammatory, Antiseborrheic, Dermatoprotective, Keratolytic, Regenerative

Treatment option: Dermatitis, Perioral Dermatitis, Zits, Seborrheic Dermatitis, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isoderm

Property	Description
Active ingredient	Isotretinoin
Form	Oral soft capsule
Pharmacological class	Systemic retinoid
General purpose	Resolving severe, persistent dermatological conditions
Origin	Synthetic derivative of Vitamin A

What is Isoderm and What Type of Drug is It?

Isoderm is a potent prescription-only medicine and a known brand containing Isotretinoin, classified as a systemic dermatological agent. It belongs to the class of retinoids, which are compounds chemically derived from Vitamin A. This medication is specifically a second-generation synthetic retinoid that is taken orally. It has powerful efficacy in modulating skin cell processes, establishing its medical recognition for addressing the most challenging cases.

As an internal, systemic treatment, Isoderm acts throughout the entire body, providing a comprehensive therapeutic approach for persistent skin issues. This systemic nature is essential for effectively managing conditions that have proven unresponsive to conventional, surface-level treatments.

Composition and Form: Isoderm's Core Active Ingredient

The medicinal core of Isoderm is the single active ingredient, Isotretinoin, known chemically as 13-cis-retinoic acid. The drug is synthetic, carefully manufactured for a precise and potent biological effect.

Isoderm is formulated as an oral soft capsule, which is necessary for its systemic delivery. This dosage form, which often utilizes an oily vehicle, is a key factor, as it is clinically required for the absorption of the highly fat-soluble Isotretinoin. This oral administration is critical for the drug's intended systemic effect. The specific soft capsule form ensures the active ingredient is delivered effectively across the gastrointestinal tract.

General Purpose and Mechanism Goal

The general purpose of Isoderm is to resolve the root causes of severe, disfiguring dermatological issues by achieving a powerful, long-term therapeutic effect. This involves its ability to influence cellular differentiation and oil production.

The drug's mechanism is designed to address the foundational pathology through two primary actions: dramatically reducing sebum production and normalizing the process of follicular keratinization (pore cell shedding). By achieving sebaceous gland atrophy (gland shrinkage), Isoderm effectively stops the excessive oil that fuels severe conditions, offering a path to sustained clearance and resolution.

Regulatory References

FDA Labeling (DailyMed)

What side effects are possible with Isoderm?

Possible Side Effects and Safety Information

Isoderm (Isotretinoin) possesses a well-defined safety profile based strictly on governmental regulatory data, structured by the nature and frequency of adverse reactions across various body systems. It is classified as a severe human teratogen, leading to the most critical safety restriction: absolute contraindication in pregnancy due to a high risk of severe birth defects.

Frequency-Classified Adverse Reactions

Classification	Examples of Documented Reactions
Very Common (1/10)	Cheilitis (dry lips), dry skin, epistaxis (nosebleeds), dry eyes, back pain, elevated blood lipids, transient liver enzyme increases.
Rare (< 1/1,000)	Depression, suicidal ideation, severe skin reactions (e.g., SJS/TEN).

Systemic Safety Concerns

Adverse effects are documented across multiple System-Organ-Classes, including the Psychiatric system (e.g., anxiety, psychosis) and the Gastrointestinal system (e.g., officially documented risk of Inflammatory Bowel Disease). Musculoskeletal effects like joint pain and myalgia are common. Laboratory Monitoring of liver function and lipid panels is required by regulatory agencies throughout therapy.

Mandatory Safety Constraints

Isoderm is subject to strict risk management programs (e.g., REMS/PPP) to prevent pregnancy. Contraindications include hepatic insufficiency and hypersensitivity. Patients must not donate blood during treatment and for a period after discontinuation. The label also advises against concomitant use with tetracyclines (risk of Pseudotumor Cerebri) and notes the potential for permanent decrease in night vision.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Isoderm (Isotretinoin) is described in official regulatory documentation, where the manifestations are generally consistent with an exaggerated, acute presentation of hypervitaminosis A toxicity. When an excessive quantity of the medication is ingested, regulatory guidance emphasizes the need for immediate action, as the resulting symptoms, though often transient, require professional assessment.

Documented Clinical Manifestations

Acute overdose may present with a specific cluster of symptoms that can resolve rapidly. Manifestations formally noted in official prescribing information and patient guides include:

Gastrointestinal System: Episodes of vomiting and abdominal pain.
Central Nervous System: Experiencing headache, dizziness, and ataxia (a loss of balance or coordination).
External Effects: Notable facial flushing and inflammation of the lips, known as cheilosis.

The official profile indicates that these acute overdose symptoms are typically non-severe and self-limiting.

Required Emergency Actions and Management

If an Isoderm overdose is suspected, the regulatory guidance mandates immediate professional consultation. Individuals must call a doctor or a poison control center right away. This regulatory instruction directs users to seek rapid toxicological or medical advice. Management of the overdose situation is officially defined as symptomatic and supportive. Regulatory bodies confirm that no specific antidote is known for acute Isotretinoin overdose, aligning the management strategy with the transient nature of the documented clinical signs.

Therapeutic Uses of Isoderm

Isoderm (isotretinoin) is a prescription medication relevant for easing severe, recalcitrant acne in situations involving certain distressing symptoms of the skin. It is generally relevant in conditions characterized by periods of heightened symptoms and is used when severe acne has not adequately responded to standard approaches. Its use is relevant for conditions presenting with disruptive symptom manifestations, including severe forms of acne, nodules, and cystic lesions.

Symptom Management and Benefits

The primary therapeutic domain is applied in addressing severe, persistent acne and assists with maintaining functional stability. It is used across domains where additional symptomatic support is needed to address the pronounced physical discomfort of severe acne. It helps manage symptom clusters that may become intense or disruptive, characterized by intense redness, significant swelling, and localized pain. This provides support that helps ease the overall symptom burden and contributes to improved day-to-day comfort.

“The medication is generally considered relevant in conditions involving episodic or fluctuating manifestations, applied when symptoms escalate temporarily.”

By addressing destructive lesion types, Isoderm contributes to easing the overall symptom load related to physical consequences, such as the risk of scarring. This supports general well-being during symptomatic phases and assists with maintaining functional stability.

Quick Fact: Support for Nodular Acne Symptoms

Eligibility and Restrictions for Use

Isoderm is authorized for use in adults and pediatric patients aged 12 years and older who have severe recalcitrant nodular acne that has not responded to conventional treatment, including systemic antibiotics. Use is not recommended for children under 12 years of age, as efficacy and safety are not officially established in this younger group.

The medicine is subject to several absolute contraindications defined in official regulatory labeling. Isoderm is strictly prohibited for use in patients who are pregnant or who may become pregnant due to the extreme risk of severe birth defects. Females of childbearing potential must enroll in and fully comply with the required official risk management and pregnancy prevention programs. The drug is also contraindicated for patients who are breastfeeding.

Non-eligibility rules also include patients with hepatic insufficiency, hypervitaminosis A, or known hypersensitivity to isotretinoin or any component. Furthermore, use is prohibited with concomitant tetracycline treatment. Patients with severe renal insufficiency or pre-existing hypertriglyceridemia require cautious use, often starting with a lower initial dose and necessitating strict medical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Isoderm (Isotretinoin) can interact with several other medications and products, which may increase the risk of adverse effects. It is essential to avoid certain combinations as specified in official regulatory labeling.

Documented Interaction Restrictions

Interacting Product Category	Restriction & Regulatory Rationale
Tetracyclines (Systemic)	Contraindicated due to the risk of developing benign intracranial hypertension (pseudotumor cerebri).
Vitamin A Preparations & Other Oral Retinoids	Avoid concurrent use due to the potential for additive toxic effects (hypervitaminosis A).
Topical Keratolytic/Abrasive Anti-Acne Agents	Avoid use on the treated area due to the risk of excessive local irritation or drying.

Procedural Constraints

Certain cosmetic procedures are restricted during and shortly after treatment with Isoderm. Patients should avoid wax depilation, dermabrasion, and laser skin treatments during therapy and for at least five to six months following discontinuation. This constraint is required because of the increased risk of scarring, hypertrophic scar formation, or dermatitis associated with these procedures while taking this medicine. These restrictions ensure the safe management of risk related to combined therapy and procedures.

Mechanism of Action

Genomic Control and Sebaceous Gland Atrophy

The drug's action begins by targeting nuclear retinoid receptors ( RARs), primarily RAR-gamma, which mediate fundamental cellular regulation. Functioning as a transcriptional modulator, Isoderm alters gene expression, leading to the selective induction of apoptosis (programmed cell death) in the sebaceous gland cells (sebocytes). This cascade results in the physical atrophy (shrinkage) of the sebaceous glands, leading to a marked reduction in sebum output.

Normalization of Follicular Cell Differentiation

In parallel, the receptor-mediated action regulates cell maturation within the pore lining. Isoderm's mechanism supports the normalization of follicular epithelial cell differentiation (keratinization), correcting abnormal cell growth and stickiness. This physiological adjustment promotes the proper shedding of dead skin cells, thereby inhibiting the formation of follicular obstructions and complementing the systemic oil reduction.

Systemic Action and Mechanistic Onset

As a systemically delivered drug operating via a genomic mechanism (altering gene transcription), its physiological effects require time to fully manifest. The mechanism is dependent on the slow, multi-step process of causing cell death and physically restructuring the tissue. Therefore, the maximum physiological effect of reduction in oil and correction of cell behavior typically requires weeks to months to manifest.

Dosage and Administration Information

How Isoderm is Used: Administration Guidelines

The usage of Isoderm (Isotretinoin) follows specific administration patterns and dosage requirements. This section details the intake and scheduling associated with the medication, without offering medical advice.

Administration Scope

Instruction	Detail
Route of Administration	The method of use is oral administration via the soft capsule form.
Dosing Schedule	The typical recommended daily dose ranges from 0.5 to 1.0 mg per kilogram of body weight (0.5-1.0 mg/kg/day). For very severe or truncal disease, the dose may be adjusted up to a maximum of 2.0 mg/kg/day.
Timing in Relation to Meals	Capsules must be taken with a meal (specifically a high-fat meal) to ensure adequate systemic absorption of the active ingredient.
Preparation Requirements	Capsules must be swallowed whole with a full glass of liquid; they should not be chewed, crushed, or sucked.
Age-Group Rules	The medication is indicated for use in patients 12 years of age and older.
Missed-Dose Rules	If a dose is missed, it should be skipped. The regular schedule should then be resumed; doses should not be doubled.

Treatment Course and Frequency

Classification	Detail
Frequency Pattern	The total daily dose is typically administered in two divided doses.
Course Duration	A single course of treatment generally lasts between 15 and 24 weeks.
Retreatment	If a second course is required, a minimum waiting period of two months (or 8 weeks) is required following the completion of the first course.

This structured protocol ensures that the drug is administered for the defined period, adhering to weight-based dosing and absorption requirements.

Recent Clinical Evidence

Research evidence / Overview of Studies for Isoderm

Evidence for Severe Recalcitrant Nodular Acne

The research behind Isoderm (Isotretinoin) primarily focuses on conditions characterized by fluctuating or episodic manifestations, specifically severe nodular acne that was studied in patients considered resistant to conventional treatments like oral antibiotics. The evidence base includes a combination of Randomized Controlled Trials (RCTs) and systematic reviews, which were used in research exploring how symptoms change over time. The studies included RCTs that compared Isoderm against placebo (an inactive pill) and other standard systemic therapies, such as oral antibiotics. These studies were designed to evaluate the drug in patients diagnosed with this particular condition. Researchers examined several outcomes, including the change in the overall number of inflammatory lesions (like nodules and cysts), as well as outcomes related to systemic or functional imbalance by monitoring standardized assessment scales.

Findings describe patterns observed in the studies, where trials reported measurements of reductions in lesion counts and that a proportion of the observed populations achieved a predefined level of clearance by the end of the treatment period. The treatment course itself was typically studied over a defined time interval of four to eight months, in research contexts involving conditions where symptoms may vary in intensity.

Long-Term Studies and Durability of Response

Research also explored the long-term course of the condition following the completion of the active treatment phase, typically over observation periods ranging from one to five years. These efforts involved large observational cohort studies to track what happens after the initial course is completed. The central focus was monitoring the relapse or recurrence rate—the frequency at which acne symptoms were observed to meet the criteria for relapse.

Studies reported how symptoms evolved in the observed populations, with data showing patterns related to relapse rates that varied widely across different study cohorts. Research has explored whether factors such as the total amount of medication received over the course of treatment are associated with different relapse frequencies. Long-term effects are not fully established, and data for certain groups remain insufficient.

Limitations and Unanswered Questions in the Research

The evidence quality varies across studies, with some older foundational trials showing methodological limitations, such as small sample sizes. Furthermore, certainty remains low regarding certain long-term outcomes. The follow-up durations were limited in many of the original RCTs. Research is ongoing to further examine the cumulative dosing strategies that are associated with long-term recurrence rates. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

How should Isoderm be stored and disposed of?

How to Store and Dispose of Isoderm?

Isoderm (isotretinoin) capsules must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

The capsules must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). It is mandatory that the medicine be protected from light and stored in the original container to maintain its integrity. The product must be kept out of the reach of children, as is standard for potent prescription medication. The medication should also be kept from freezing.

Disposal Instructions

Unused or expired Isoderm should not be flushed down a toilet or sink. The preferred method for disposal is using a drug take-back program. If a take-back option is unavailable, the FDA recommends mixing the capsules with an undesirable substance, placing the mixture in a sealed container, and discarding it in the household trash. All disposal must comply with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Germany

Poland

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z